- Home
- Results news
- Sanofi Consumer Healthcare India
- Q2 FY26 results
Sanofi Consumer Healthcare India Q2 FY26 results: net profit up 39.8% to ₹62.90 crore, revenue up 46.3%
Sanofi Consumer Healthcare India Limited reported standalone Q2 FY26 revenue of ₹233.90 crore, up 46.3% from ₹159.90 crore in Q2 FY25, while net profit rose 39.8% to ₹62.90 crore. EBITDA increased to ₹85 crore, but its margin declined 3.2 percentage points to 36.3%; basic EPS was ₹27.31.
Key points
- Q2 FY26 revenue was ₹233.90 crore, up 46.3% from ₹159.90 crore in Q2 FY25.
- EBITDA rose 34.7% to ₹85 crore, while EBITDA margin fell 3.2 percentage points to 36.3%.
- Net profit rose 39.8% to ₹62.90 crore from ₹45 crore in Q2 FY25; basic EPS was ₹27.31.
- Against Q1 FY26, revenue increased 5.9% to ₹233.90 crore and net profit rose 3.6% to ₹62.90 crore.
- For H1 FY26, revenue rose 17.2% to ₹627.4 crore and net profit increased 27.0% to ₹173.6 crore.
How did Sanofi Consumer Healthcare India perform in Q2 FY26?
Sanofi Consumer Healthcare India reported standalone revenue of ₹233.90 crore in Q2 FY26, up ₹74 crore or 46.3% from ₹159.90 crore in Q2 FY25. Total income was ₹236.9 crore, compared with ₹164.1 crore a year earlier, while EBITDA rose ₹21.90 crore or 34.7% to ₹85 crore. The EBITDA margin declined from 39.5% to 36.3%.
Profit before tax increased ₹22.90 crore or 37.4% to ₹84.10 crore, and net profit rose ₹17.90 crore or 39.8% to ₹62.90 crore. Basic EPS increased from ₹19.54 to ₹27.31. The net profit margin was 26.9%, down 1.2 percentage points from 28.1%.
Against Q1 FY26, revenue rose ₹13 crore or 5.9% to ₹233.90 crore and EBITDA increased ₹14.80 crore or 21.1% to ₹85 crore. The EBITDA margin improved 4.5 percentage points to 36.3%. Net profit was up ₹2.20 crore or 3.6% at ₹62.90 crore, while basic EPS increased ₹0.95 to ₹27.31. The filing presented the results as standalone and unaudited figures for the quarter ended 30 September 2025.
| ₹ crore | Q2 FY26 | Q1 FY26 | Q2 FY25 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 233.90 | 220.90 | 159.90 | +46.3% | +5.9% |
| Other income | 3 | 5.60 | 4.20 | −28.6% | −46.4% |
| Total expenses | 152.80 | 154.20 | 101.70 | +50.2% | −0.9% |
| EBITDA | 85 | 70.20 | 63.10 | +34.7% | +21.1% |
| EBITDA margin | 36.3% | 31.8% | 39.5% | −3.2 pp | +4.5 pp |
| Profit before tax | 84.10 | 78.90 | 61.20 | +37.4% | +6.6% |
| Tax | 21.20 | 18.20 | 16.20 | +30.9% | +16.5% |
| Net profit | 62.90 | 60.70 | 45 | +39.8% | +3.6% |
| EPS (₹) | 27.31 | 26.36 | 19.54 | +39.8% | +3.6% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Sanofi Consumer Healthcare India's costs and profit?
Total expenses rose ₹51.10 crore or 50.2% from ₹101.70 crore in Q2 FY25 to ₹152.80 crore in Q2 FY26. Cost of materials increased ₹22.40 crore or 158.9% to ₹36.50 crore, employee cost was up ₹4.30 crore or 15.7% at ₹31.70 crore, and other expenses rose ₹24.70 crore or 80.5% to ₹55.40 crore.
Finance costs fell ₹2.80 crore or 82.4% to ₹0.60 crore, while depreciation rose ₹1.80 crore or 120.0% to ₹3.30 crore. Other income fell ₹1.20 crore or 28.6% to ₹3 crore. Q2 FY26 recorded no exceptional item, compared with a ₹1.20 crore exceptional charge in Q2 FY25.
Tax expense increased ₹5 crore or 30.9% to ₹21.20 crore. Despite the higher cost lines, profit before tax rose ₹22.90 crore or 37.4% to ₹84.10 crore and net profit rose ₹17.90 crore or 39.8% to ₹62.90 crore. The filing does not state reasons for the movements in the individual cost lines or other income.
| ₹ crore | Q2 FY26 | Q2 FY25 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 36.50 | 14.10 | +22.40 | +158.9% |
| Employee cost | 31.70 | 27.40 | +4.30 | +15.7% |
| Finance costs | 0.60 | 3.40 | −2.80 | −82.4% |
| Depreciation | 3.30 | 1.50 | +1.80 | +120.0% |
| Other expenses | 55.40 | 30.70 | +24.70 | +80.5% |
| Total expenses | 152.80 | 101.70 | +51.10 | +50.2% |
| Other income | 3 | 4.20 | −1.20 | −28.6% |
| Tax | 21.20 | 16.20 | +5 | +30.9% |
| Exceptional items | none | −1.20 (charge) |
Source: Company's results filing (XBRL).
How did the first half of FY26 go?
For H1 FY26, standalone revenue rose ₹91.9 crore or 17.2% to ₹627.4 crore from ₹535.5 crore in H1 FY25. Total income increased ₹97.7 crore or 18.0% to ₹641.2 crore. Profit before tax rose ₹45.8 crore or 24.9% to ₹229.8 crore, and net profit increased ₹36.9 crore or 27.0% to ₹173.6 crore. Basic EPS was ₹75.38, compared with ₹59.36. The filed results cover the nine months ended 30 September 2025 and were unaudited.
| ₹ crore | H1 FY26 | H1 FY25 | Change |
|---|---|---|---|
| Revenue from operations | 627.40 | 535.50 | +17.2% |
| Profit before tax | 229.80 | 184 | +24.9% |
| Net profit | 173.60 | 136.70 | +27.0% |
| EPS (₹) | 75.38 | 59.36 | +27.0% |
Source: Company's results filing (XBRL).
How has Sanofi Consumer Healthcare India done over the last 6 quarters?
Revenue rose year on year in each of the last two quarters, as did profit. Across the six quarters from Q1 FY25 to Q2 FY26, revenue was lowest at ₹159.9 crore in Q2 FY25 and highest at ₹233.9 crore in Q2 FY26. Net profit was lowest at ₹29.0 crore in Q1 FY25 and highest at ₹62.9 crore in Q2 FY26.
The EBITDA margin peaked at 39.5% in Q2 FY25 and bottomed at 31.8% in Q1 FY26. It subsequently recovered to 36.3% in Q2 FY26, while revenue and net profit reached their highest levels in the six-quarter period. The filing does not provide a reason for the movement in the margin.
How did Sanofi Consumer Healthcare India shares react?
The filing was released after market hours on 12 November 2025. From the price when it appeared, the stock rose 2.1% after 5 minutes and 4.4% after both 15 and 30 minutes. On the reaction day, it closed 7.6% above its pre-results close, compared with a 0.1% fall for the median Pharmaceuticals stock; the excess move was 7.8 percentage points.
Earlier reaction-day moves were mixed: the stock rose 12.8% on 4 August 2025, rose 0.2% on 2 May 2025, fell 2.1% on 20 February 2025, fell 0.5% on 12 November 2024 and rose 4.3% on 18 September 2024.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | +2.1% | |
| 15 minutes | +4.4% | |
| 30 minutes | +4.4% | |
| Reaction day | +7.6% | −0.1% |
| Next day | +3.9% | −0.5% |
| 5 days | +3.1% | −1.6% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 4 August 2025 | +12.8% |
| 2 May 2025 | +0.2% |
| 20 February 2025 | −2.1% |
| 12 November 2024 | −0.5% |
| 18 September 2024 | +4.3% |
Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
Among 160 Pharmaceuticals companies compared for the quarter, the median revenue growth was 8.8%. Sanofi Consumer Healthcare India’s revenue growth was higher than the median; 136 peers grew more slowly than the company and 24 grew faster than the company.
Of the 159 peers for which profit was compared, 97 reported higher profit. The peer comparison was recorded as of 5 November 2026, while the company’s results were announced on 12 November 2025.
| Sanofi Consumer Healthcare India revenue growth (YoY) | +46.3% |
|---|---|
| Median of 160 other Pharmaceuticals companies | +8.8% |
| Companies with slower revenue growth than Sanofi Consumer Healthcare India | 136 of 160 |
| Companies with faster revenue growth than Sanofi Consumer Healthcare India | 24 of 160 |
| Companies whose net profit rose | 97 of 159 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Sanofi Consumer Healthcare India's revenue in Q2 FY26?
Revenue from operations was ₹233.90 crore, up 46.3% from ₹159.90 crore in Q2 FY25 (standalone).
Did Sanofi Consumer Healthcare India make a profit in Q2 FY26?
Yes. Net profit was ₹62.90 crore, against a net profit of ₹45 crore in Q2 FY25.
What was Sanofi Consumer Healthcare India's EPS in Q2 FY26?
Basic earnings per share were ₹27.31, against ₹19.54 in Q2 FY25.
How did Sanofi Consumer Healthcare India shares react to the Q2 FY26 results?
On the reaction day the stock moved +7.6% from the previous close; the median Pharmaceuticals stock moved −0.1%.
When did Sanofi Consumer Healthcare India announce its Q2 FY26 results?
On 12 November 2025, in a filing to the NSE.
Sources
- Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2025 (BSE, 5 November 2025) · PDF
- Outcome of Board Meeting (NSE, 12 November 2025) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.